Third Quarter Fiscal Year 2026
Filed Aug 14, 2026Outlook Therapeutics reported third-quarter fiscal 2026 net loss of $20.3 million and is preparing a planned U.S. launch of FDA-approved LYTENAVA before the end of calendar 2026.
FDA approval and U.S. launch preparation are central strategic milestones, and adjusted net loss narrowed from the prior-year quarter, but quarterly revenue was $9, gross profit was $(8), and the company reported a $20.3 million GAAP net loss.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Revenues, netGAAP | $9 | – | – |
| Cost of revenuesGAAP | 17 | – | – |
| Gross profitGAAP | $(8) | – | – |
| Research and developmentGAAP | $3,251 | – | – |
| Selling, general and administrativeGAAP | 7,551 | – | – |
| Loss from operationsGAAP | $(10,810) | – | – |
| Loss on equity method investmentGAAP | 41 | – | – |
| Interest expenseGAAP | — | – | – |
| Loss from change in fair value of promissory notesGAAP | 1,103 | – | – |
| Loss from change in fair value of warrant liabilityGAAP | 7,036 | – | – |
| Loss on extinguishment of debtGAAP | 1,329 | – | – |
| Net loss before income taxGAAP | $(20,319) | – | – |
| Income tax expenseGAAP | — | – | – |
| Net loss attributable to common stockholdersGAAP | $(20.3 million) | – | – |
| Net loss per share of common stock, basic and dilutedGAAP | $(0.15) per basic and diluted share | – | – |
| Weighted average shares outstanding, basic and dilutedGAAP | 136,743 | – | – |
| Adjusted net loss attributable to common stockholdersnon-GAAP | $(10.9 million) | – | – |
| Adjusted net loss attributable to common stockholders per share of common stock, basic and dilutednon-GAAP | $(0.09) per basic and diluted share | – | – |
| Nine months ended June 30 revenues, netGAAP | $(1,071) | – | – |
| Nine months ended June 30 cost of revenuesGAAP | 196 | – | – |
| Nine months ended June 30 gross profitGAAP | $(1,267) | – | – |
| Nine months ended June 30 research and developmentGAAP | 11,386 | – | – |
| Nine months ended June 30 selling, general and administrativeGAAP | 25,668 | – | – |
| Nine months ended June 30 loss from operationsGAAP | $(38,321) | – | – |
| Nine months ended June 30 net loss attributable to common stockholdersGAAP | $(47,830) | – | – |
| Nine months ended June 30 net loss per share of common stock, basic and dilutedGAAP | $(0.51) | – | – |
| Nine months ended June 30 adjusted net loss attributable to common stockholdersnon-GAAP | $(38,446) | – | – |
| Nine months ended June 30 adjusted net loss attributable to common stockholders per share of common stock, basicnon-GAAP | $(0.42) | – | – |
By 2030 and calendar 2026 outlook
- NoteManagement believes LYTENAVA has the potential to exceed $500 million in annual U.S. sales by 2030.
- NoteThe Company plans a U.S. commercial launch of LYTENAVA before the end of calendar 2026.
- NoteThe Company plans to submit an application for a permanent Healthcare Common Procedure Coding System or HCPCS code by October 1, 2026.
- NoteThe Company is preparing for a planned launch in the Netherlands later in 2026.
- NoteIn Switzerland, Mediconsult is leading regulatory and commercial activities in support of an anticipated launch in 2027.
What drove it
- FDA approval of LYTENAVA, described as the only FDA-approved ophthalmic bevacizumab for wet age-related macular degeneration in the United States.
- U.S. launch preparation includes payer engagement, commercial-supply scaling, customer segmentation and targeting, and building a commercial organization.
- The Company has commenced commercial launch of LYTENAVA in Germany, Austria, and the United Kingdom.
- The adjusted net loss excludes loss on extinguishment of debt and changes in fair value of warrants and convertible promissory notes.
Concerns
- Third-quarter revenues, net were $9, compared with $1,505 in the same period last year.
- Third-quarter gross profit was $(8), compared with 1,065 in the same period last year.
- The Company reported net loss attributable to common stockholders of $20.3 million.
- The U.S. go-to-market strategy is designed to address an evolving biosimilar landscape, affordability considerations, and the potential for additional market entrants.
- Certain European Union Member States require pricing and reimbursement approval before LYTENAVA can be sold.
What to watch
- Progress toward the planned U.S. launch before the end of calendar 2026.
- Submission of the permanent HCPCS code application by October 1, 2026 and progress on reimbursement and market access.
- Commercialization progress in Germany, Austria, and the United Kingdom, as well as the planned Netherlands launch later in 2026.
- Execution against the stated potential to exceed $500 million in annual U.S. LYTENAVA sales by 2030.
- Use of approximately $51.1 million of net proceeds from the August 2026 public offering.
Balance sheet and cash flow
- Cash and cash equivalents were $11,242 as of June 30, 2026, compared with $8,083 as of September 30, 2025.
- Total assets were $26,185 as of June 30, 2026, compared with $18,584 as of September 30, 2025.
- Current liabilities were $28,679 as of June 30, 2026, compared with $45,815 as of September 30, 2025.
- Total stockholders' deficit was $(10,393) as of June 30, 2026, compared with $(32,188) as of September 30, 2025.
- Subsequent to quarter end, in August 2026, the Company announced a public offering of 55,555,556 shares of common stock and accompanying warrants to purchase 55,555,556 shares of common stock at a combined public offering price of $0.99 per share and accompanying warrant, for approximately $51.1 million of net proceeds, after deducting underwriting discounts and commissions and other estimated offering expenses.
- Cash and cash equivalents of $11.2 million as of June 30, 2026 did not include the proceeds from the public offering.
Analysis
Outlook Therapeutics' third-quarter fiscal 2026 report centers on the FDA approval of LYTENAVA and preparation for a planned U.S. commercial launch before the end of calendar 2026. Management is expanding payer engagement, scaling commercial supply, establishing customer targeting, and building a retina-focused commercial team. The company also plans to submit an application for a permanent HCPCS code by October 1, 2026, positioning reimbursement and access as key launch execution priorities.
The reported operating results remain loss-making and revenue was limited. Revenues, net were $9 for the three months ended June 30, 2026, compared with $1,505 in the prior-year period, while gross profit was $(8), compared with 1,065. Loss from operations was $(10,810), compared with $(15,749), with research and development of $3,251 versus $7,135 and selling, general and administrative expense of 7,551 versus 9,679.
GAAP net loss attributable to common stockholders was $20.3 million, or $0.15 per basic and diluted share, compared with $20.2 million, or $0.55 per basic and diluted share. The GAAP result included $1.1 million of loss from change in fair value of promissory notes, $1.3 million of loss on extinguishment of debt, and $7.0 million of loss from change in fair value of warrant liability. Adjusted net loss attributable to common stockholders was $10.9 million, or $0.09 per basic and diluted share, compared with adjusted net loss of $15.8 million, or $0.44 per basic and diluted share, in the third fiscal quarter of 2025.
Liquidity is a central consideration ahead of launch. The company had cash and cash equivalents of $11.2 million as of June 30, 2026, excluding the subsequent August 2026 offering. That offering involved 55,555,556 shares of common stock and accompanying warrants to purchase 55,555,556 shares at $0.99 per share and accompanying warrant, for approximately $51.1 million of net proceeds. The company reported current liabilities of $28,679 and total stockholders' deficit of $(10,393) as of June 30, 2026.
Commercial progress is underway in Germany, Austria, and the United Kingdom, while the company is preparing for a planned Netherlands launch later in 2026 and an anticipated Swiss launch in 2027 through Mediconsult. Management stated that LYTENAVA has the potential to exceed $500 million in annual U.S. sales by 2030. The figures that warrant the closest attention are U.S. launch timing, HCPCS and reimbursement progress, early adoption by targeted retina practices, European commercialization, and the deployment of the offering proceeds.
Management, verbatim
FDA approval of LYTENAVA marks a defining moment for Outlook Therapeutics and creates a significant opportunity for the Company in the United States.
Bob Jahr, Chief Executive Officer of Outlook Therapeutics
Our priorities are clear: build an exceptional commercial team with deep retina and launch experience, prepare for our planned U.S. launch by the end of calendar 2026, and execute a strategy that reflects today’s competitive and evolving wet AMD treatment landscape.
Bob Jahr, Chief Executive Officer of Outlook Therapeutics
Not in the filing
stated, not guessed- Segment revenue, segment year-over-year changes, segment quarter-over-quarter changes, and segment drivers were not reported.
- Gross margin was not reported.
- Prior-quarter comparisons for reported quarterly metrics were not reported.
- Year-over-year percentage changes and quarter-over-quarter percentage changes were not reported for the financial metrics.
- Operating cash flow was not reported.
- Free cash flow was not reported.
- Debt balance was not reported.
- Share repurchases and dividends were not reported.
- Quantitative revenue, gross-margin, operating-expense, and tax-rate guidance was not reported.
- Previous-quarter outlook was not provided.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.